IRD Stock — Opus Genetics, Inc.

Opus Genetics, Inc. (IRD)

Updated October 16, 2026.

IRD is a Stock. Its deepest 1-year drawdown was 49.2%.

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to treat inherited retinal diseases and other ophthalmic disorders, with programs in various stages from early-stage clinical trials through preclinical research. The company does not currently distribute dividends. This security appeals to investors seeking exposure to early-stage biotech development rather than current income generation.

IRD performance

Returns are updating. IRD's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 49.2%.

IRD key facts

Asset type

Stock

Asset class

Equity

Inception date

11/30/2004

Distribution frequency

None

Last close

$3.84 (as of 2026-10-16)

Market cap

$319,471,960

Average volume

2520736.0

Payment date

11/06/2020

Beta

0.62

Payout ratio

0.0%

Forward P/E

12.0048

EPS

$-1.27

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

IRD risks and drawbacks

The deepest 1-year drawdown on record here is 49.2%.

Who may consider IRD — and who may not

It is a weaker fit for investors who need monthly cash flow (IRD does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on IRD

• All tickers starting with I

Tagged: Healthcare.

Frequently asked questions